Bedrijfsoverzicht
Actinium Pharmaceuticals, Inc. is a biotechnology enterprise dedicated to the development of antibody radiation conjugates and targeted radiotherapies designed to enhance clinical outcomes for patients who have exhausted existing oncology treatment options. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant regulatory hurdles and reliance on successful clinical trial outcomes. As of the latest data, the company holds a market capitalization of $33.88M, reports annual revenue of $90,000, and employs a workforce of 25 individuals. These financial figures indicate that Actinium is a micro-cap entity with negligible revenue relative to its market valuation, suggesting that its stock price is driven primarily by the potential future value of its clinical-stage product candidates rather than current operational cash flow.
Financiële gezondheid
The company reported revenue of $90,000 for the trailing twelve months, accompanied by a net income of $-33,887,000 and an EBITDA of $-36,064,000. The substantial disparity between the minimal revenue figure and the significant negative net income reveals an operational cost structure dominated by research and development expenses, general administrative costs, and likely clinical trial expenditures typical of early-stage biotechnology firms. The free cash flow stands at $-12,849,375, indicating a net cash outflow that limits the company's immediate financial flexibility and necessitates external capital raising to sustain operations. Despite the negative income statement, the balance sheet demonstrates a robust liquidity position with cash reserves of $48.00M against total debt of $1.69M. The gross margin is recorded at 100.0%, reflecting that the cost of goods sold is negligible compared to the cost of revenue in this pre-commercial stage, whereas the operating margin of -40274.4% and profit margin of 0.0% highlight the heavy overhead burden relative to current sales. The debt-to-equity ratio is 21.62, yet the absolute debt level remains low compared to cash holdings, suggesting the balance sheet is not aggressively leveraged despite the negative equity implications of losses. The current ratio of 6.20 indicates a highly conservative short-term liquidity position, meaning the company holds more than six times the current assets necessary to cover its current liabilities. Finally, the return on equity is -167.0% and the return on assets is -35.2%, metrics that mathematically reflect the dilution of shareholder value due to cumulative losses but do not necessarily indicate poor management effectiveness in the context of a company investing heavily in clinical progression.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -1.92, a metric that typically does not provide meaningful valuation insight for loss-making companies and implies an earnings trajectory that is not yet positive. The price-to-book ratio stands at 4.30, indicating that the market values the company at a premium of over four times its net asset value, which is common for biotechnology firms where intangible assets like intellectual property and clinical data are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 376.50 and the EV/EBITDA of 0.35 suggest that the market is pricing the stock based on future growth potential rather than current profitability or asset backing. The stock has traded between a 52-week high of $1.95 and a 52-week low of $0.95, and without a specific current price provided in the facts, the valuation range indicates significant volatility within a narrow band. The beta value of -0.21 is an anomalous metric for equities, suggesting a statistical correlation that moves inversely to the broader market, though such a negative beta implies the price movement does not follow standard market correlation models and may be influenced by specific sector-wide sentiment or low trading volume.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, which precludes any quantitative comparison of earnings expansion relative to top-line growth at this specific point in time. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of not available and a payout ratio of 0.0%. This zero payout ratio confirms that the company retains all available resources to reinvest into research and development programs rather than returning capital to investors. Consequently, the overall growth and income profile of Actinium Pharmaceuticals, Inc. is characterized by a total lack of current income generation and an undefined growth rate, relying entirely on the successful advancement of its two clinical stage product candidates to transition from a loss-making entity to a profitable one in the future.